T1D Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 15
- Investments
- 30
- Portfolio
- 20
- Exits
- 6
T1D Fund General Information
Description
Founded in 2016, T1D Fund is a venture capital firm based in Boston, Massachusetts. The firm seeks to invest in the healthcare sector and invests in products and therapies that enable people with T1D, or those at risk of developing it, to lead a more normal and longer life.
Contact Information
Website
www.t1dfund.org
Year Founded
2016
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- Boston, MA
- United States
T1D Fund Investments (30)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Code Bio | 20-Apr-2021 | Seed Round | 0000 | Biotechnology | Generating Revenue | |
| 0000000 | 09-Feb-2021 | 00000 00000 | 0000 | Therapeutic Devices | Generating Revenue | |
| 0000000 | 28-Jan-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | |
| 000 000000000000 | 01-Dec-2020 | 0000 00000 | 00.00 | Drug Delivery | Startup | 00000 000000 |
| 00000000 000000000 | 30-Nov-2020 | 0000 00000 | 00.00 | Drug Delivery | Generating Revenue | 00000 000000 |
| 000000 00000000000 | 30-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Startup | |
| 000000000 | 08-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - General | |
| 00000 000000000000 | 17-Aug-2020 | 00000 00000 | 000.00 | Drug Delivery | Generating Revenue | |
| Diogenx | 16-Jun-2020 | Seed Round | 000 | Drug Discovery | Pre-Clinical Trials | 00000 000000 |
| SQZ Biotech | 18-May-2020 | Later Stage VC | 0000 | Drug Delivery | Generating Revenue/Not Profitable | 000000 000000 00.0 |
T1D Fund Exits (6)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Immunocore | 05-Feb-2021 | IPO | 00000 |
| 00000000 | 08-Jan-2021 | 000 00 00000000 | |
| 000 0000000 | 30-Oct-2020 | 000 | 000.00 |
| 0000000 0000000000 | 17-Jul-2020 | 000 | 00000 |
| Semma Therapeutics | 10-Oct-2019 | Merger/Acquisition | 00000 |
| Provention Bio | 24-Jul-2018 | IPO | 000.00 |
T1D Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialT1D Fund Team (19)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Steven Peter MD | Managing Director & Chairman | 0 | Boston, MA | ||
| Katie Ellias | Managing Director | 0 | 0 | 0 | Boston, MA |
| Bruce Buckingham MD | Partner & Advisor | Boston, MA | |||
| Carmella Evans-Molina Ph.D | Partner & Advisor | Boston, MA | |||
| Chantal Mathieu Ph.D | Partner & Advisor | Boston, MA |
T1D Fund Co-Investors (122)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| ARCH Venture Partners | 3 | 0 | 0 |
|
|
| Polaris Partners | 0 | 0 | 0 |
|
|
| Alexandria Venture Investments | 0 |
|
|
||
| Eli Lilly and Company Foundation | 0 |
|
|
||
| Roche Venture Fund | 0 | 0 |
|
|